Overview

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Status:
Completed

Trial end date:
2014-06-02

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pfizer

Collaborator:

UCB Pharma

Treatments:

Inotuzumab Ozogamicin
Rituximab